|
1
|
Fouad YA and Aanei C: Revisiting the
hallmarks of cancer. Am J Cancer Res. 7:1016–1036. 2017.PubMed/NCBI
|
|
2
|
Mittal D, Gubin MM, Schreiber RD and Smyth
MJ: New insights into cancer immunoediting and its three component
phases-elimination, equilibrium and escape. Curr Opin Immunol.
27:16–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vaziri Fard E, Ali Y, Wang XI, Saluja K, H
Covinsky M, Wang L and Zhang S: Tumor-infiltrating lymphocyte
volume is a better predictor of disease-free survival than stromal
tumor-infiltrating lymphocytes in invasive breast carcinoma. Am J
Clin Pathol. 152:656–665. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen Y, Wang J, Wang X, Li X, Song J, Fang
J, Liu X, Liu T, Wang D, Li Q, et al: Pik3ip1 is a negative immune
regulator that inhibits antitumor T cell immunity. Clin Cancer Res.
25:6180–6194. 2019.PubMed/NCBI
|
|
5
|
Alsaab HO, Sau S, Alzhrani R, Tatiparti K,
Bhise K, Kashaw SK and Iyer AK: PD-1 and PD-L1 checkpoint signaling
inhibition for cancer immunotherapy: Mechanism, combinations, and
clinical outcome. Front Pharmacol. 8:5612017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guo L, Zhang H and Chen B: Nivolumab as
Programmed Death-1 (PD-1) inhibitor for targeted immunotherapy in
tumor. J Cancer. 8:410–416. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McDermott J and Jimeno A: Pembrolizumab:
PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today
(Barc). 51:7–20. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Karachaliou N, Gonzalez-Cao M, Crespo G,
Drozdowskyj A, Aldeguer E, Gimenez-Capitan A, Teixido C,
Molina-Vila MA, Viteri S, De Los Llanos Gil M, et al: Interferon
gamma, an important marker of response to immune checkpoint
blockade in non-small cell lung cancer and melanoma patients. Ther
Adv Med Oncol. Jan 18–2018.(Epub ahead of print). doi:
10.1177/1758834017749748. View Article : Google Scholar
|
|
9
|
Azim HA and Ibrahim AS: Breast cancer in
Egypt, China and Chinese: Statistics and beyond. J Thorac Dis.
6:864–866. 2014.PubMed/NCBI
|
|
10
|
Prensner JR and Chinnaiyan AM: The
emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jin HY and Xiao C: MicroRNA mechanisms of
action: What have we learned from mice? Front Genet. 6:3282015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sempere LF, Christensen M, Silahtaroglu A,
Bak M, Heath CV, Schwartz G, Wells W, Kauppinen S and Cole CN:
Altered MicroRNA expression confined to specific epithelial cell
subpopulations in breast cancer. Cancer Res. 67:11612–11620. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Asghari F, Haghnavaz N, Baradaran B,
Hemmatzadeh M and Kazemi T: Tumor suppressor microRNAs: Targeted
molecules and signaling pathways in breast cancer. Biomed
Pharmacother. 81:305–317. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao YS, Yang WC, Xin HW, Han JX and Ma
SG: MiR-182-5p knockdown targeting PTEN inhibits cell proliferation
and invasion of breast cancer cells. Yonsei Med J. 60:148–157.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cao MQ, You AB, Zhu XD, Zhang W, Zhang YY,
Zhang SZ, Zhang KW, Cai H, Shi WK, Li XL, et al: miR-182-5p
promotes hepatocellular carcinoma progression by repressing FOXO3a.
J Hematol Oncol. 11:122018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li N, Nan CC, Zhong XY, Weng JQ, Fan HD,
Sun HP, Tang S, Shi L and Huang SX: miR-182-5p promotes growth in
oral squamous cell carcinoma by inhibiting CAMK2N1. Cell Physiol
Biochem. 49:1329–1341. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu X, Wu J, Li S, Hu Z, Xu X, Zhu Y, Liang
Z, Wang X, Lin Y, Mao Y, et al: Downregulation of microRNA-182-5p
contributes to renal cell carcinoma proliferation via activating
the AKT/FOXO3a signaling pathway. Mol Cancer. 13:1092014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kopp F and Mendell JT: Functional
classification and experimental dissection of long noncoding RNAs.
Cell. 172:393–407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fang H, Disteche CM and Berletch JB: X
Inactivation and escape: Epigenetic and structural features. Front
Cell Dev Biol. 7:2192019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Samir A, Salama E and El Tayebi HM: The
long non-coding RNA XIST: A new cornerstone in carcinogenesis. J
Mol Genet Med. 12:22018.
|
|
21
|
Zhou K, Li S, Du G, Fan Y, Wu P, Sun H and
Zhang T: LncRNA XIST depletion prevents cancer progression in
invasive pituitary neuroendocrine tumor by inhibiting bFGF via
upregulation of microRNA-424-5p. Onco Targets Ther. 12:7095–7109.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xing F, Liu Y, Wu SY, Wu K, Sharma S, Mo
YY, Feng J, Sanders S, Jin G, Singh R, et al: Loss of XIST in
breast cancer activates MSN-c-Met and reprograms microglia via
exosomal miRNA to promote brain metastasis. Cancer Res.
78:4316–4330. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Salama EA, Adbeltawab RE and El Tayebi HM:
XIST and TSIX: Novel cancer immune biomarkers in
PD-L1-overexpressing breast cancer patients. Front Oncol.
9:14592019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu Y, Zhang W, Li A, Chen Y, Ou Q, He Z,
Zhang Y, Liu R, Yao H and Song E: Association of long noncoding RNA
biomarkers with clinical immune subtype and prediction of
immunotherapy response in patients with cancer. JAMA Netw Open.
3:e2021492020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, Li Z, Chen M, Chen H, Zhong Q,
Liang L and Li B: lncRNA TCL6 correlates with immune cell
infiltration and indicates worse survival in breast cancer. Breast
Cancer. 27:573–585. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang M, Wang N, Song P, Fu Y, Ren Y, Li Z
and Wang J: LncRNA GATA3-AS1 facilitates tumour progression and
immune escape in triple-negative breast cancer through
destabilization of GATA3 but stabilization of PD-L1. Cell Prolif.
53:e128552020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gayen S, Maclary E, Buttigieg E, Hinten M
and Kalantry S: A primary role for the Tsix lncRNA in maintaining
random X-chromosome inactivation. Cell Rep. 11:1251–1265. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao ZB, Chen F and Bai XF: Long noncoding
RNA MALAT1 regulates hepatocellular carcinoma growth under hypoxia
via sponging MicroRNA-200a. Yonsei Med J. 60:727–734. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ji P, Diederichs S, Wang W, Böing S,
Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, et
al: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict
metastasis and survival in early-stage non-small cell lung cancer.
Oncogene. 22:8031–8041. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Argadal OG, Mutlu M, Ak Aksoy S, Kocaeli
H, Tunca B, Civan MN, Egeli U, Cecener G, Bekar A, Taskapilioglu
MO, et al: Long noncoding RNA MALAT1 may be a prognostic biomarker
in IDH1/2 wild-type primary glioblastomas. Bosn J Basic Med Sci.
20:63–69. 2020.PubMed/NCBI
|
|
31
|
Amin MB, Edge S, Greene F, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC Cancer Staging Manual. 8th edition.
Springer International Publishing; 2017, View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mittendorf EA, Philips AV, Meric-Bernstam
F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM,
Akcakanat A, et al: PD-L1 expression in triple-negative breast
cancer. Cancer Immunol Res. 2:361–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Blackburn SD, Shin H, Haining WN, Zou T,
Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA and Wherry
EJ: Coregulation of CD8+ T cell exhaustion by multiple inhibitory
receptors during chronic viral infection. Nat Immunol. 10:29–37.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Buchbinder EI and Desai A: CTLA-4 and PD-1
pathways: Similarities, differences, and implications of their
inhibition. Am J Clin Oncol. 39:98–106. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Linsley PS, Brady W, Urnes M, Grosmaire
LS, Damle NK and Ledbetter JA: CTLA-4 is a second receptor for the
B cell activation antigen B7. J Exp Med. 174:561–569. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
van der Merwe PA, Bodian DL, Daenke S,
Linsley P and Davis SJ: CD80 (B7-1) binds both CD28 and CTLA-4 with
a low affinity and very fast kinetics. J Exp Med. 185:393–403.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sasidharan Nair V, Toor SM, Ali BR and
Elkord E: Dual inhibition of STAT1 and STAT3 activation
downregulates expression of PD-L1 in human breast cancer cells.
Expert Opin Ther Targets. 22:547–557. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Monneur A, Gonçalves A and Bertucci F:
PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer. Bull
Cancer. 105:263–274. 2018.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Alegre ML, Frauwirth KA and Thompson CB:
T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol. 1:220–228.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang X, Teng F, Kong L and Yu J: PD-L1
expression in human cancers and its association with clinical
outcomes. Onco Targets Ther. 9:5023–5039. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Takahashi T, Tagami T, Yamazaki S, Uede T,
Shimizu J, Sakaguchi N, Mak TW and Sakaguchi S: Immunologic
self-tolerance maintained by CD25(+)CD4(+) regulatory T cells
constitutively expressing cytotoxic T lymphocyte-associated antigen
4. J Exp Med. 192:303–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Krummel MF and Allison JP: CTLA-4
engagement inhibits IL-2 accumulation and cell cycle progression
upon activation of resting T cells. J Exp Med. 183:2533–2540. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wing K, Onishi Y, Prieto-Martin P,
Yamaguchi T, Miyara M, Fehervari Z, Nomura T and Sakaguchi S:
CTLA-4 control over Foxp3+ regulatory T cell function. Science.
322:271–275. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mao H, Zhang L, Yang Y, Zuo W, Bi Y, Gao
W, Deng B, Sun J, Shao Q and Qu X: New insights of CTLA-4 into its
biological function in breast cancer. Curr Cancer Drug Targets.
10:728–736. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Duraiswamy J, Kaluza KM, Freeman GJ and
Coukos G: Dual blockade of PD-1 and CTLA-4 combined with tumor
vaccine effectively restores T-cell rejection function in tumors.
Cancer Res. 73:3591–3603. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kao SC, Cheng YY, Williams M, Kirschner
MB, Madore J, Lum T, Sarun KH, Linton A, McCaughan B, Klebe S, et
al: Tumor suppressor microRNAs contribute to the regulation of
PD-L1 expression in malignant pleural mesothelioma. J Thorac Oncol.
12:1421–1433. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Schütz F, Stefanovic S, Mayer L, von Au A,
Domschke C and Sohn C: PD-1/PD-L1 pathway in breast cancer. Oncol
Res Treat. 40:294–297. 2017. View Article : Google Scholar
|
|
50
|
Krishnan K, Steptoe AL, Martin HC, Wani S,
Nones K, Waddell N, Mariasegaram M, Simpson PT, Lakhani SR,
Gabrielli B, et al: MicroRNA-182-5p targets a network of genes
involved in DNA repair. RNA. 19:230–242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yee D, Shah KM, Coles MC, Sharp TV and
Lagos D: MicroRNA-155 induction via TNF-alpha and IFN-gamma
suppresses expression of programmed death ligand-1 (PD-L1) in human
primary cells. J Biol Chem. 292:20683–20693. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhan Y, Li X, Liang X, Li L, Cao B, Wang
B, Ma J, Ding F, Wang X, Pang D and Liu Z: MicroRNA-182 drives
colonization and macroscopic metastasis via targeting its
suppressor SNAI1 in breast cancer. Oncotarget. 8:4629–4641. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Robainas M, Otano R, Bueno S and
Ait-Oudhia S: Understanding the role of PD-L1/PD1 pathway blockade
and autophagy in cancer therapy. Onco Targets Ther. 10:1803–1807.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wu F, Yin Z, Yang L, Fan J, Xu J, Jin Y,
Yu J, Zhang D and Yang G: Smoking induced extracellular vesicles
release and their distinct properties in non-small cell lung
cancer. J Cancer. 10:3435–3443. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Cha YJ and Shim HS: PD-L1 expression and
CD8+ tumor-infiltrating lymphocytes are associated with ALK
rearrangement and clinicopathological features in inflammatory
myofibroblastic tumors. Oncotarget. 8:89465–89474. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Peters S, Kerr KM and Stahel R: PD-1
blockade in advanced NSCLC: A focus on pembrolizumab. Cancer Treat
Rev. 62:39–49. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Li L, Chen H, Gao Y, Wang YW, Zhang GQ,
Pan SH, Ji L, Kong R, Wang G, Jia YH, et al: Long noncoding RNA
MALAT1 promotes aggressive pancreatic cancer proliferation and
metastasis via the stimulation of autophagy. Mol Cancer Ther.
15:2232–2243. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wei S, Wang K, Huang X and Zhao Z and Zhao
Z: LncRNA MALAT1 contributes to non-small cell lung cancer
progression via modulating miR-200a-3p/programmed death-ligand 1
axis. Int J Immunopathol Pharmacol. 33:20587384198596992019.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Gordon MA, Babbs B, Cochrane DR, Bitler BG
and Richer JK: The long non-coding RNA MALAT1 promotes ovarian
cancer progression by regulating RBFOX2-mediated alternative
splicing. Mol Carcinog. 58:196–205. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Xie H, Liao X, Chen Z, Fang Y, He A, Zhong
Y, Gao Q, Xiao H, Li J, Huang W and Liu Y: LncRNA MALAT1 inhibits
apoptosis and promotes invasion by antagonizing miR-125b in bladder
cancer cells. J Cancer. 8:3803–3811. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ou X, Gao G, Bazhabayi M, Zhang K, Liu F
and Xiao X: MALAT1 and BACH1 are prognostic biomarkers for
triple-negative breast cancer. J Cancer Res Ther. 15:1597–1602.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Xiping Z, Bo C, Shifeng Y, Feijiang Y,
Hongjian Y, Qihui C and Binbin T: Roles of MALAT1 in development
and migration of triple negative and Her-2 positive breast cancer.
Oncotarget. 9:2255–2267. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Bamodu OA, Huang WC, Lee WH, Wu A, Wang
LS, Hsiao M, Yeh CT and Chao TY: Aberrant KDM5B expression promotes
aggressive breast cancer through MALAT1 overexpression and
downregulation of hsa-miR-448. BMC Cancer. 16:1602016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zheng L, Zhang Y, Fu Y, Gong H, Guo J, Wu
K, Jia Q and Ding X: Long non-coding RNA MALAT1 regulates BLCAP
mRNA expression through binding to miR-339-5p and promotes poor
prognosis in breast cancer. Biosci Rep. 39:BSR201812842019.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Du Y, Weng XD, Wang L, Liu XH, Zhu HC, Guo
J, Ning JZ and Xiao CC: LncRNA XIST acts as a tumor suppressor in
prostate cancer through sponging miR-23a to modulate RKIP
expression. Oncotarget. 8:94358–94370. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Jiang L, Yu X, Ma X, Liu H, Zhou S, Zhou
X, Meng Q, Wang L and Jiang W: Identification of transcription
factor-miRNA-lncRNA feed-forward loops in breast cancer subtypes.
Comput Biol Chem. 78:1–7. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Schouten PC, Vollebergh MA, Opdam M,
Jonkers M, Loden M, Wesseling J, Hauptmann M and Linn SC: High XIST
and Low 53BP1 expression predict poor outcome after high-dose
alkylating chemotherapy in patients with a BRCA1-like breast
cancer. Mol Cancer Ther. 15:190–198. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yang C, Wu K, Wang S and Wei G: Long
non-coding RNA XIST promotes osteosarcoma progression by targeting
YAP via miR-195-5p. J Cell Biochem. 119:5646–5656. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Liu WG and Xu Q: Long non-coding RNA XIST
promotes hepatocellular carcinoma progression by sponging
miR-200b-3p. Eur Rev Med Pharmacol Sci. 23:9857–9862.
2019.PubMed/NCBI
|
|
71
|
Zhou K, Yang J, Li X and Chen W: Long
non-coding RNA XIST promotes cell proliferation and migration
through targeting miR-133a in bladder cancer. Exp Ther Med.
18:3475–3483. 2019.PubMed/NCBI
|
|
72
|
Xu Z, Xu J, Lu H, Lin B, Cai S, Guo J,
Zang F and Chen R: LARP1 is regulated by the XIST/miR-374a axis and
functions as an oncogene in non-small cell lung carcinoma. Oncol
Rep. 38:3659–3667. 2017.PubMed/NCBI
|
|
73
|
Kulkarni P, Dasgupta P, Bhat NS, Shahryari
V, Shiina M, Hashimoto Y, Majid S, Deng G, Saini S, Tabatabai ZL,
et al: Elevated miR-182-5p associates with renal cancer cell
mitotic arrest through diminished MALAT-1 expression. Mol Cancer
Res. 16:1750–1760. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Wang QM, Lian GY, Song Y, Huang YF and
Gong Y: LncRNA MALAT1 promotes tumorigenesis and immune escape of
diffuse large B cell lymphoma by sponging miR-195. Life Sci.
231:1163352019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zhang X, Ma G, Liu J and Zhang Y:
MicroRNA-182 promotes proliferation and metastasis by targeting
FOXF2 in triple-negative breast cancer. Oncol Lett. 14:4805–4811.
2017. View Article : Google Scholar : PubMed/NCBI
|
